A Mouse Model of Glycogen Storage Disease Type IX-Beta: A Role for Phkb in Glycogenolysis

被引:6
|
作者
Arends, Charles J. [1 ,2 ]
Wilson, Lane H. [1 ,3 ]
Estrella, Ana [1 ]
Kwon, Oh Sung [4 ,5 ]
Weinstein, David A. [1 ]
Lee, Young Mok [1 ,2 ]
机构
[1] Univ Connecticut, Sch Med, Dept Pediat, Farmington, CT 06030 USA
[2] Univ Connecticut, Dept Genet & Genome Sci, Hlth Ctr, Farmington, CT 06030 USA
[3] Univ Penn, Perelman Sch Med, Dept Med, Gene Therapy Program, Philadelphia, PA 19104 USA
[4] Univ Connecticut, Dept Kinesiol, Storrs, CT 06269 USA
[5] Univ Connecticut, Ctr Aging, Dept Orthpaed Surg, Hlth Ctr, Farmington, CT 06030 USA
关键词
glycogenolysis; hepatomegaly; hypoglycemia; ketosis; glucose; PHOSPHORYLASE-KINASE DEFICIENCY; LIVER GLYCOGENOSIS; NATURAL-HISTORY; MUTATIONS; VARIABILITY; ISOFORM; MUSCLE; RAT;
D O I
10.3390/ijms23179944
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glycogen storage disease type IX (GSD-IX) constitutes nearly a quarter of all GSDs. This ketotic form of GSD is caused by mutations in phosphorylase kinase (PhK), which is composed of four subunits (alpha, beta, gamma, delta). PhK is required for the activation of the liver isoform of glycogen phosphorylase (PYGL), which generates free glucose-1-phosphate monomers to be used as energy via cleavage of the alpha -(1,4) glycosidic linkages in glycogen chains. Mutations in any of the PhK subunits can negatively affect the regulatory and catalytic activity of PhK during glycogenolysis. To understand the pathogenesis of GSD-IX-beta, we characterized a newly created PHKB knockout (Phkb(-/-)) mouse model. In this study, we assessed fasting blood glucose and ketone levels, serum metabolite concentrations, glycogen phosphorylase activity, and gene expression of gluconeogenic genes and fibrotic genes. Phkb(-/-) mice displayed hepatomegaly with lower fasting blood glucose concentrations. Phkb(-/-) mice showed partial liver glycogen phosphorylase activity and increased sensitivity to pyruvate, indicative of partial glycogenolytic activity and upregulation of gluconeogenesis. Additionally, gene expression analysis demonstrated increased lipid metabolism in Phkb(-/-) mice. Gene expression analysis and liver histology in the livers of old Phkb(-/-) mice (>40 weeks) showed minimal profibrogenic features when analyzed with age-matched wild-type (WT) mice. Collectively, the Phkb(-/-) mouse recapitulates mild clinical features in patients with GSD-IX-beta. Metabolic and molecular analysis confirmed that Phkb(-/-) mice were capable of sustaining energy homeostasis during prolonged fasting by using partial glycogenolysis, increased gluconeogenesis, and potentially fatty acid oxidation in the liver.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Molecular diagnosis of glycogen storage disease type IX using a glycogen storage disease gene panel
    Kim, Tae Hyeong
    Kim, Kwang Yeon
    Kim, Man Jin
    Seong, Moon-Woo
    Park, Sung Sup
    Moon, Jin Soo
    Ko, Jae Sung
    EUROPEAN JOURNAL OF MEDICAL GENETICS, 2020, 63 (06)
  • [2] Liver histology in children with glycogen storage disorders type VI and IX
    Degrassi, Irene
    Deheragoda, Maesha
    Creegen, David
    Mundy, Helen
    Mustafa, Ahlam
    Vara, Roshni
    Hadzic, Nedim
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (01) : 86 - 93
  • [3] Benign or not benign? Deep phenotyping of liver Glycogen Storage Disease IX
    Fernandes, Samuela A.
    Cooper, Gabrielle E.
    Gibson, Rebecca Anne
    Kishnani, Priya S.
    MOLECULAR GENETICS AND METABOLISM, 2020, 131 (03) : 299 - 305
  • [4] Glycogen storage disease type IX and growth hormone deficiency presenting as severe ketotic hypoglycemia
    Hodax, Juanita K.
    Uysal, Serife
    Quintos, Jose Bernardo
    Phornphutkul, Chanika
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2017, 30 (02) : 247 - 251
  • [5] Aggressive therapy improves cirrhosis in glycogen storage disease type IX
    Tsilianidis, Laurie A.
    Fiske, Laurie M.
    Siegel, Sara
    Lumpkin, Chris
    Hoyt, Kate
    Wasserstein, Melissa
    Weinstein, David A.
    MOLECULAR GENETICS AND METABOLISM, 2013, 109 (02) : 179 - 182
  • [6] Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV
    Yi, Haiqing
    Gao, Fengqin
    Austin, Stephanie
    Kishnani, Priya S.
    Sun, Baodong
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2016, 9 : 31 - 33
  • [7] Glycogen storage disease type IX: High variability in clinical phenotype
    Beauchamp, Nicholas James
    Dalton, Ann
    Ramaswami, Uma
    Nimikoski, Harri
    Mention, Karine
    Kenny, Patricio
    Kolho, Kaija-Leena
    Raiman, Julian
    Walter, John
    Treacy, Eileen
    Tanner, Stuart
    Sharrard, Mark
    MOLECULAR GENETICS AND METABOLISM, 2007, 92 (1-2) : 88 - 99
  • [8] Expected or unexpected clinical findings in liver glycogen storage disease type IX: distinct clinical and molecular variability
    Inci, Asli
    Kilic Yildirim, Gonca
    Cengiz Ergin, Filiz Basak
    Sari, Sinan
    Egritas Gurkan, Odul
    Okur, Ilyas
    Biberoglu, Gursel
    Bukulmez, Aysegul
    Ezgu, Fatih Suheyl
    Dalgic, Buket
    Tumer, Leyla
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2022, 35 (04) : 451 - 462
  • [9] A detailed characterization of the adult mouse model of glycogen storage disease Ia
    Salganik, Susan V.
    Weinstein, David A.
    Shupe, Thomas D.
    Salganik, Max
    Pintilie, Dana G.
    Petersen, Bryon E.
    LABORATORY INVESTIGATION, 2009, 89 (09) : 1032 - 1042
  • [10] Aberrant apolipoprotein C-III glycosylation in glycogen storage disease type III and IX
    Ondruskova, Nina
    Honzik, Tomas
    Kolarova, Hana
    Pakanova, Zuzana
    Mucha, Jan
    Zeman, Jiri
    Hansikova, Hana
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 82 : 135 - 141